Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05020860 · ClinicalTrials.gov registry record · Phase 2
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
A Phase 2 study of Breast Cancer and Triple Negative Breast Cancer, sponsored by Baylor Breast Care Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 185
- Enrollment target
- 2
- Study locations
NCT05020860: Recruiting Phase 2 study of Breast Cancer and Triple Negative Breast Cancer, sponsored by Baylor Breast Care Center.
NCT05020860 is a Phase 2 study of Breast Cancer and Triple Negative Breast Cancer that is actively recruiting participants, run by Baylor Breast Care Center. The registered enrollment target is 185 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05020860, a Phase 2 study of Breast Cancer and Triple Negative Breast Cancer, is actively recruiting participants, sponsored by Baylor Breast Care Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 185 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to learn whether clinical response (the amount a tumor shrinks based on imaging or tumor measurements obtained by physical exam) predicts pathologic response (the amount of tumor remaining when surgery is performed) in participants with breast cancer who are receiving chemotherapy prior to surgery.
Primary Outcome
Clinical tumor measurements are tumor measurements obtain via imaging (mammogram or ultrasound) or by physical exam. Pathologic response is the amount of tumor remaining at the time of surgery, as determined by the pathologist.
Conditions Studied
Interventions
- DRUG Trastuzumab
- DRUG Carboplatin
- DRUG Doxorubicin
- DRUG Paclitaxel
- DRUG Pertuzumab
Study Locations (2)
Texas
- Harris Health System - Smith Clinic - Houston
- O'Quinn Medical Tower - McNair Campus - Dan L Duncan Comprehensive Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2023-04-18 |
| Est. Completion | 2029-11 |
| Phase | Phase 2 |
What NCT05020860 shows while recruiting
NCT05020860 is an interventional study that assigns participants to a tested intervention. The registered 185 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower).
The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Trastuzumab is the first listed.
NCT05020860 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05020860 about?
NCT05020860 is a clinical study titled "Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer". The purpose of this study is to learn whether clinical response (the amount a tumor shrinks based on imaging or tumor measurements obtained by physical exam) predicts pathologic response (the amount of tumor remaining when surgery is performed) in participants with breast cancer who are receiving ch...
What is the current status of trial NCT05020860?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 185 participants. The study started on 2023-04-18. Estimated completion is 2029-11.
What conditions does trial NCT05020860 study?
This clinical trial studies the following conditions: Breast Cancer, Triple Negative Breast Cancer, HER2-positive Breast Cancer, Breast Cancer Female, Breast Neoplasm.
What interventions are being tested in trial NCT05020860?
The interventions under investigation include: Trastuzumab (DRUG), Carboplatin (DRUG), Doxorubicin (DRUG), Paclitaxel (DRUG), Pertuzumab (DRUG).
Who is sponsoring clinical trial NCT05020860?
This trial is sponsored by Baylor Breast Care Center, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05020860 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05020860's enrollment target sits among peer trials
185 397th of 1224 higher than 826 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04041154 · 185 participants · NA
Behavioral and Neural Representations of Subjective Effort Cost
- NCT04484272 · 185 participants · NA
A Stress and Pain Self-management m-Health App for Adult Outpatients With Sickle Cell Disease
- NCT05793541 · 185 participants · NA
Just-in-time Interventions for Reducing Short-term Suicide Risk
- NCT05897424 · 185 participants · Phase 2
Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI